Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.

@article{Mookerjee2016TreatmentWN,
  title={Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.},
  author={Rajeshwar P Mookerjee and Marco Pavesi and Karen Louise Thomsen and Gautam Mehta and J Macnaughtan and Flemming Bendtsen and Minneke J. Coenraad and Jan {\vS}perl and Pere Gin{\`e}s and Richard Moreau and Vicente Arroyo and Rajiv Jalan},
  journal={Journal of hepatology},
  year={2016},
  volume={64 3},
  pages={
          574-82
        }
}
BACKGROUND & AIMS Non-selective beta blockers (NSBBs) have been shown to have deleterious outcomes in patients with refractory ascites, alcoholic hepatitis and spontaneous bacterial peritonitis leading many physicians to stop the drug in these cases. Acute-on-chronic liver failure (ACLF) is characterized by systemic inflammation and high mortality. As NSBBs may have beneficial effects on gut motility and permeability and, systemic inflammation, the aims of this prospective, observational study… CONTINUE READING
34 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Treatment with non-selective beta-blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic

  • R. P. Mookerjee, M. Pavesi, +9 authors R. Jalan
  • 2015

Similar Papers

Loading similar papers…